CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Results of Operations and Financial Condition

42

CELSION CORPORATION (NASDAQ:CLSN) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition.

On March 16, 2017, Celsion Corporation issued a press release
reporting its financial results for the year ended December 31,
2016.A copy of the press release is furnished as Exhibit 99.1 to
this Current Report on Form 8-K.

On March 9, 2017, Celsion Corporation announced it would hold a
conference call on March 16, 2017 to discuss its financial
results for the year ended December 31, 2016 and provide a
business update.The conference call will also be broadcast live
on the internet at http://www.celsion.com.

The information in this report, including the exhibit hereto, is
being furnished and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, or
otherwise subject to the liabilities of that Section or Sections
11 and 12(a)(2) of the Securities Act of 1933, as amended. Such
information shall not be incorporated by reference into any
filing with the Securities and Exchange Commission made by
Celsion Corporation, whether made before or after the date
hereof, regardless of any general incorporation language in such
filing.

The press release contains forward-looking statements which
involve certain risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by
such statements. Please refer to the cautionary note in the press
release regarding these forward-looking statements.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits.

Exhibit

No.

Description

99.1

Press Release titled Celsion Corporation Reports Year End
2016 Financial Resultsand Provides Business Updateissued by
Celsion Corporation on March 16, 2017.


About CELSION CORPORATION (NASDAQ:CLSN)

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

CELSION CORPORATION (NASDAQ:CLSN) Recent Trading Information

CELSION CORPORATION (NASDAQ:CLSN) closed its last trading session up +0.035 at 0.325 with 6,363,485 shares trading hands.

An ad to help with our costs